---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063735"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:54:45.950319+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q3 revenue down 41% YoY to $282K; gross profit up 71% to $108K

## Summary
- Net loss of $1.8M narrowed from $2.6M in Q3 2022; operating expenses fell 30% to $1.9M.
- Gross margin improved to 38% from 13% YoY on price increases and supply-chain optimization.
- Cash and equivalents totaled $5.2M as of Sept 30, 2023.
- Announced partnerships with InStep Health and Amerisource Bergen; NASDAQ compliance regained after reverse stock split.

## SEC filing metadata
- accession: 0000950170-23-063735
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/0000950170-23-063735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/tivc-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063735
- JSON: https://secwatch.observer/filing/0000950170-23-063735.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063735.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported the third quarter 2023 ended September 30, 2023 results: revenue $282 thousand.
  - Period: the third quarter 2023 ended September 30, 2023
  - Revenue: $282 thousand
  - Result: reported results
  source text: medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”). Third Quarter 2023 Financial Highlights • Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. • Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. • Gross Margin of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/0000950170-23-063735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.